<DOC>
	<DOCNO>NCT01702649</DOCNO>
	<brief_summary>RPX2003 ( biapenem ) study combination beta-lactamase inhibitor treat bacterial infection , include due multi-drug resistant bacteria .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Intravenous RPX2003 ( Biapenem ) Healthy Adult Subjects</brief_title>
	<detailed_description>The worldwide spread resistance antibiotic among Gram-negative bacteria , particularly member ESKAPE group pathogen , result crisis treatment hospital acquire infection . In particular , recent dissemination serine carbapenemase ( e.g. , KPC ) Enterobacteriaceae US hospital pose considerable threat carbapenems member beta-lactam class antimicrobial agent . Rempex develop fix combination antibiotic carbapenem ( RPX2003 biapenem ) plus new beta-lactamase inhibitor ( RPX7009 ) activity serine beta-lactamase , include KPC . This Phase 1 study ass safety , tolerability pharmacokinetics biapenem , administer alone , healthy adult subject .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Biapenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<criteria>Healthy adult male and/or female , 18 55 year age Body mass index ( BMI ) ≥ 18.5 ≤ 29.9 ( kg/m2 ) weight 55.0 100.0 kg ( inclusive ) . Medically healthy clinically insignificant screen result Nontobacco/nicotinecontaining product user minimum 6 month prior Day 1 . Sexually abstinent use acceptable method birth control History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease . History presence alcoholism drug abuse within 2 year prior Day 1 . Hypersensitivity idiosyncratic reaction compound related study drug ( e.g . betalactam antibiotic penicillin , carbapenems , etc ) . History seizure ( e.g. , epilepsy ) . Use overthecounter ( OTC ) medication , include herbal product vitamin , within 7 day prior Day 1 . Up 2 gram per day acetaminophen allow acute event discretion PI . Blood donation significant blood loss ( i.e. , &gt; 500 mL ) within 56 day prior Day 1 . Subjects abnormalities laboratory value screen checkin ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>